A wearable device for transdermal product supply comprises a head, which houses two ultrasonic resonators in resonance, with an outer cavity. A first, more distal resonator emits towards the skin at a first frequency and a second, more proximal resonator surrounds the cavity and emits parallel to the skin at a second frequency. One frequency is high-frequency sonophoresis (HFS) and the other is low-frequency sonophoresis (LFS). The second resonator comprises a hole in order to enable the waves from the first resonator to pass through. The waves from the second resonator pass through the head, the hole and the cavity, bouncing off an opposite area of the head and interfering with the waves from the first resonator. The interference between the waves creates a stationary field which increases the permeability of the skin, enabling a device with a reduced size to be incorporated into a wearable.

Apparatus, kits, and methods for administering a substance are presented. A device for administering a substance includes an elongated body having a proximal end and a distal end, the elongated body defining an internal chamber extending between the proximal end and the distal end to direct the substance to the distal end, the distal end to connect with a tip, the tip to be at least partially inserted into an orifice of a body lumen of a subject, the tip having a shape configured to reduce leakage of the substance from the orifice upon the at least partial insertion. The tip includes an opening to pass the substance from the internal chamber into the body lumen; and a transducer to emit an ultrasound wave from the tip into the body lumen, thereby administering the substance to tissue in the body lumen.

A method of treating a patient having cancer cells has the step of directing sound energy from one or more acoustic shock wave or pressure pulse treatments into the patient targeting the cancer cells in at least one tumor or in the blood to cause the patient’s immune system to identify the cancer cells as foreign objects and trigger a natural healing mechanism of the patient’s immune system to destroy the foreign objects. Wherein targeting the at least one tumor initiates cellular communication resulting in an unmasking of all cancer cells in the patient’s body by destroying a cloaking capability of the cancer cells which made the cancer cells indistinguishable from normal cells allowing the cancer cells to hide from the immune system prior to the one or more acoustic shock wave or pressure pulse treatments.

Apparatus, kits, and methods for administering a substance are presented. A device for administering a substance includes an elongated body having a proximal end and a distal end, the elongated body defining an internal chamber extending between the proximal end and the distal end to direct the substance to the distal end, the distal end to connect with a tip, the tip to be at least partially inserted into an orifice of a body lumen of a subject, the tip having a shape configured to reduce leakage of the substance from the orifice upon the at least partial insertion. The tip includes an opening to pass the substance from the internal chamber into the body lumen; and a transducer to emit an ultrasound wave from the tip into the body lumen, thereby administering the substance to tissue in the body lumen.

Medical devices comprising applicators that present a microneedle array and a separate electroporation array configured to simultaneously contact a tissue surface, a fluidic system connected to the microneedle array, and an electronic system connected to the electroporation array, for the coordinated delivery of a fluid biologic and electroporation energy to a tissue.

Pressure waves are applied to intersect a focal volume or pressure field with a targeted tissue in conjunction with introducing a treatment agent into the targeted tissue to increase permeability of cells in the targeted tissue and cause more rapid absorption of the treatment agent in the targeted tissue.

Systems and methods for targeting specific cell types by selective application of ultrasonic harmonic excitation at a resonance frequency (“oncotripsy”) for the specific cell types are presented. The systems and the methods result in permeabilization, lysis, and/or death of the targeted specific cell types by using ultrasonic harmonic excitations that have a frequency and a pulse duration specifically tuned to disrupt nuclear membranes of the targeted specific cell types by inducing a destructive vibrational response therein while leaving non-targeted cell types intact. Target cells may be neoplastic.

Methods and systems are described for producing non-invasive and targeted neuronal lesions using magnetic resonance and acoustic energy. Imaging data corresponding to a region of interest is obtained, the region of interest within an imaging subject. Information indicative of a target region within the region of interest is received from the obtained imaging data. Focused acoustic energy directed to the target region within the region of interest is generated to disrupt a barrier between a therapeutic agent and parenchymal tissue in response to insonification by the focused acoustic energy, the therapeutic agent comprising a neurotoxin and microbubbles.

This application is drawn to a method of using an isoform NELL-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis.

A treatment system can include a channel generation system configured to expose an infected region of a target tissue with a laser beam traveling along an optical axis and focused at a focal volume located in or adjacent to the target tissue. The laser beam can have a wavelength ranging from about 100 nm to about 400 nm. The laser beam can be configured to generate at least a first channel in the infected region. The treatment system can also include a detection system configured to detect a first radiation generated by one or more of (i) the target tissue, (ii) a fungi coupled to the infected region in the target tissue, and (iii) an adjacent tissue located proximal to the target tissue as a result of interaction with the laser beam. The treatment system can also include a delivery system configured to deposit an active treatment agent in the at least first channel.